BioCorRx (BICX) Cost of Revenue (2010 - 2026)

BioCorRx has disclosed Cost of Revenue across 16 years of filings, most recently posting $25184.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $25184.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $25184.0 (changed N/A YoY), and the FY2024 annual result was $1667.0, down 95.37% from the prior year.
• Cost of Revenue came in at $25184.0 for Q1 2026 at BioCorRx, up from $1667.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $25184.0 in Q1 2026 to a low of $1535.0 in Q1 2022.
• The 4-year median for Cost of Revenue is $6278.5 (2022), against an average of $7811.6.
• Across the five-year window, Cost of Revenue soared 465.21% in 2023 and sank 80.79% in 2024, its largest moves.
• BioCorRx's Cost of Revenue stood at $8676.0 in 2022, then jumped by 50.45% to $13053.0 in 2023, then slumped by 87.23% to $1667.0 in 2024, then jumped by 1410.74% to $25184.0 in 2026.
• The last three Cost of Revenue figures came in at $25184.0 (Q1 2026), $1667.0 (Q1 2024), and $13053.0 (Q4 2023), per Business Quant data.